Catalent Inc Stock News

Catalent (CTLT) inks a merger agreement with Novo Holdings, under which the latter will acquire Catalent for $16.5 billion.

U.S. drug regulators in November found quality control lapses at the Bloomington, Indiana factory of contract drug manufacturer Catalent , including discovery of a "pest" on the manufacturing line, ac

Novo Nordisk (NYSE:NVO)'s takeover of three production sites through the acquisition of Catalent Inc (NYSE:CTLT) is a sensible move, analysts say, and will help meet demand for its flagship weight los

Catalent (CTLT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro

The pharmaceuticals manufacturing leader is being acquired by Novo Holdings. The transaction should close toward the end of 2024.

The shares of pharmaceutical concern Catalent Inc (NYSE:CTLT) are surging today, after news that Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is purchasing the company for $11.5

Shares of syringe maker Catalent (CTLT) soared 10% in early trading after it signed a deal to be sold to the controlling shareholder of Novo Nordisk (NVO) for $16.5 billion.

Catalent (NYSE: CTLT ) stock is climbing higher on Monday after the company agreed to sell itself to Novo Nordisk (NYSE: NVO ) parent Novo Holdings for $16.5 billion. The transaction will have Novo Ho

Catalent is the main supplier of fill-finish work, which involves filling and packaging syringes and injection pens, for Novo Nordisk's Wegovy.

Shares in drug manufacturer Catalent Inc (NYSE:CTLT) soared over 11% in pre-market trading as news broke that Novo Nordisk (NYSE:NVO)'s controlling shareholder was to buy the firm for US$16.5 billion.

Novo Holdings will acquire Catalent for $63.50 a share in cash.

Novo Holdings, the holding company of Novo Nordisk , will buy contract drugmaker Catalent in an all-cash transaction worth $11.5 billion in equity value to expand its capacity for popular weight-loss

Novo Holdings, the controlling shareholder of Novo Nordisk NVO, -1.80%, said it's buying Catalent CTLT, +2.67% for $16.5 billion in cash, or $63.50 per Catalent share, a 16.5% premium to Friday's clos

Novo Nordisk's CEO Lars Fruergaard Jorgensen confirmed on Wednesday that Catalent's Indiana plant in the United States has started filling injection pens for its obesity drug Wegovy, helping to boost

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release financ